Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Second Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 43 current clinical trials in our China register. 40 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Ipilimumab, Pembrolizumab and Durvalumab, idarubicin, bevacizumab. The most-studied condition is Lung Cancer.

ClinicalTrials.gov trials by status

Recruiting4093%
Not yet open37%

Trials by phase

Phase 21228%
Phase 11126%
Phase 3512%
Phase 1/249%
Phase EARLY_PHASE137%
Phase 2/337%
Not applicable25%
Observational25%
Phase 412%

Clinical trials sponsored by Second Affiliated Hospital of Guangzhou Medical University

43 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200 · Hepatocellular Carcinoma Non-resectable Drugs: Lenvatinib, TACE	Phase 3	Recruiting	2022-11	China
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors NCT05187338 · ClinicalTrials.gov ↗ · Lung Cancer, Liver Cancer, Colorectal Cancer Drugs: Durvalumab, Ipilimumab, Pembrolizumab	Phase 1/2	Recruiting	2021-11	China
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors NCT06195293 · ClinicalTrials.gov ↗ · Solid Tumor, Adult Drug: Neoantigen Polypeptide Vaccine	Phase 1	Recruiting	2024-06	China
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression NCT03198546 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, CAR	Phase 1	Recruiting	2017-07	China
SIRT for Potentially Resectable HCC NCT05994859 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	2023-08	China
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray NCT03192501 · ClinicalTrials.gov ↗ · Lung Cancer, Gene Abnormality, Gene Product Sequence Variation	Observational	Recruiting	2017-07	China
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05985798 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 3	Recruiting	2023-08	China
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT NCT06482801 · ClinicalTrials.gov ↗ · Liver Cancer, Antibody Drugs: Durvalumab, idarubicin, bevacizumab, Ipilimumab, Pembrolizumab	Phase 2	Recruiting	2024-06	China
GPC3/Mesothelin-CAR-γδT Cells Against Cancers NCT06196294 · ClinicalTrials.gov ↗ · Pancreas Cancer, Lung Cancer, Liver Cancer	Phase 1	Recruiting	2024-05	China
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC NCT05608213 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable Drug: Lenvatinib	Phase 3	Recruiting	2022-11	China
Anti-cancer DC Cell Vaccination to Treat Solid Tumors NCT06477614 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, DC	Phase 1	Recruiting	2024-06	China
A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome NCT07675746 · ClinicalTrials.gov ↗ · Dravet Syndrome (DS)	Phase EARLY_PHASE1	Recruiting	2025-12	China
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. NCT06492408 · ClinicalTrials.gov ↗ · Hepatic Cancer, Surgery	Phase 2	Recruiting	2024-07	China
Y-90 SIRT for Unresectable HCC Larger Than 7cm NCT06707233 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-Resectable	Phase 2	Recruiting	2024-12	China
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors NCT04952272 · ClinicalTrials.gov ↗ · Lung Cancer, Hepatocellular Carcinoma, Solid Tumor	Phase 1	Recruiting	2021-03	China
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers NCT05779917 · ClinicalTrials.gov ↗ · Pancreas Cancer, CAR-T Cell Therapy, Mesothelin	Phase 1	Recruiting	2023-03	China
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717 · ClinicalTrials.gov ↗ · Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent	Phase 1	Recruiting	2022-06	China
Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis NCT05882708 · ClinicalTrials.gov ↗ · Sepsis, Ivabradine, Hemodynamics	Phase 4	Recruiting	2023-06	China
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers NCT03198052 · ClinicalTrials.gov ↗ · Lung Cancer, Cancer, Immunotherapy Drug: EGFR	Phase 1	Recruiting	2017-07	China
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. NCT06492421 · ClinicalTrials.gov ↗ · Lung Cancer, Surgery, Non-small Cell Lung Cancer	Phase 2	Recruiting	2024-07	China
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT NCT06483347 · ClinicalTrials.gov ↗ · Lung Cancer, Inoperable Disease Drugs: Durvalumab, idarubicin, bevacizumab, Ipilimumab, Pembrolizumab	Phase 2	Recruiting	2024-04	China
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors NCT03755739 · ClinicalTrials.gov ↗ · Hepatocarcinoma, Lung Cancer, Melanoma	Phase 2/3	Recruiting	2018-11	China
Interventional Software for Multi-immunotherapy of Solid Tumors NCT06478108 · ClinicalTrials.gov ↗ · Lung Cancer, Liver Cancer, Solid Tumor, Adult	Phase 2/3	Recruiting	2024-04	China
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors NCT06195384 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1	Recruiting	2024-05	China
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma NCT03949231 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 3	Recruiting	2019-01	China
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC NCT06397235 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Recruiting	2024-05	China
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC NCT03769129 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Not applicable	Recruiting	2018-11	China
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors NCT04842812 · ClinicalTrials.gov ↗ · Liver Cancer, Lung Cancer, Breast Cancer	Phase 1	Recruiting	2021-01	China
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT NCT06492395 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 3	Recruiting	2024-08	China
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC) NCT03952065 · ClinicalTrials.gov ↗ · Head/Neck Neoplasm	Phase 2/3	Recruiting	2019-01	China
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC NCT06397222 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Recruiting	2024-05	China
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors NCT03778814 · ClinicalTrials.gov ↗ · Nonsmall Cell Lung Cancer, Solid Tumor, Adult	Phase 1	Recruiting	2018-12	China
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs NCT04770207 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Solid Tumor, Adult	Phase 2	Recruiting	2020-11	China
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer NCT05341492 · ClinicalTrials.gov ↗ · EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer	Phase EARLY_PHASE1	Recruiting	2022-05	China
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I NCT03882840 · ClinicalTrials.gov ↗ · Anti-cancer Cell Immunotherapy, T Cell and NK Cell	Phase 1/2	Recruiting	2019-01	China
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors NCT04803318 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Hepatocellular Carcinoma	Phase 2	Recruiting	2021-01	China
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT NCT06904183 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Recruiting	2025-04	China
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC NCT06904196 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Recruiting	2025-04	China
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus NCT07374328 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: Semaglutide, Sitagliptin	Phase 1/2	Recruiting	2025-06	China
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC NCT05060796 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase EARLY_PHASE1	Recruiting	2019-09	China
Stem Cell Derived Exome for Treatment of Diabetic Foot NCT06480123 · ClinicalTrials.gov ↗ · Diabetic Foot, Stem Cell	Phase 1/2	Not yet open	2024-08	China
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma NCT07657273 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drug: NRT6003	Phase 2	Not yet open	2026-06	China
Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus NCT06966830 · ClinicalTrials.gov ↗ · Epilepsy, Status Epilepticus	Observational	Not yet open	2025-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Second Affiliated Hospital of Guangzhou Medical University trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Ipilimumab3 Pembrolizumab3 Durvalumab, idarubicin, bevacizumab2 Lenvatinib2 Durvalumab1 EGFR1 NRT60031 Neoantigen Polypeptide Vaccine1 Semaglutide1 Sitagliptin1 TACE1

Conditions in Second Affiliated Hospital of Guangzhou Medical University trials

51 conditions

Lung Cancer10 Hepatocellular Carcinoma Non-resectable8 Solid Tumor, Adult8 Liver Cancer6 Hepatocellular Carcinoma6 Pancreas Cancer3 Immunotherapy2 Cancer2 Surgery2 Non Small Cell Lung Cancer2 Colorectal Cancer1CAR1GPC3 Gene Inactivation1Gene Abnormality1Gene Product Sequence Variation1Antibody1Mesothelioma1DC1Dravet Syndrome (DS)1Hepatic Cancer1Hepatocellular Carcinoma Non-Resectable1 Solid Tumor1 CAR-T Cell Therapy1Mesothelin1

By trial register

Register	Trials	Recruiting
Clinical trials in China	43	40

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Lung Cancer

Sponsor	Trials
Shanghai Chest Hospital	9
Shanghai Pulmonary Hospital, Shanghai, China	8
The First Affiliated Hospital of Guangzhou Medical University	6
Intuitive Surgical	4
Guangdong Provincial People's Hospital	3
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	3
All India Institute of Medical Sciences	2
Liu Huang	2
Zhou Chengzhi	2
Queen's University, Belfast	1

Sponsors with the most current trials registered for this condition.

Questions about Second Affiliated Hospital of Guangzhou Medical University trials

How many clinical trials does Second Affiliated Hospital of Guangzhou Medical University sponsor?

Second Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 43 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Second Affiliated Hospital of Guangzhou Medical University trials recruiting?

Yes. 40 of its 43 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Second Affiliated Hospital of Guangzhou Medical University testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are Ipilimumab (3), Pembrolizumab (3), Durvalumab, idarubicin, bevacizumab (2), Lenvatinib (2) and Durvalumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Second Affiliated Hospital of Guangzhou Medical University clinical trials